NEW YORK / Apr 02, 2024 / Business Wire / Oscar Health, Inc. (“Oscar”) (NYSE: OSCR), a leading healthcare technology company, will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.
Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows:
The call will be archived and available on Oscar’s investor relations website (www.ir.hioscar.com) following May 7, 2024 for a period of 90 days.
About Oscar Health
Oscar Health, Inc. (“Oscar”) is the first health insurance company built around a full stack technology platform and a relentless focus on serving its members. At Oscar, our mission is to make a healthier life accessible and affordable for all. Headquartered in New York City, Oscar has been challenging the healthcare system's status quo since our founding in 2012. The company’s member-first philosophy and innovative approach to care has earned us the trust of approximately 1.3 million members, as of January 2024. We offer Individual & Family and Small Group plans, and +Oscar, our full stack technology platform, to others within the provider and payor space. Our vision is to refactor healthcare to make good care cost less. Refactor is a term used in software engineering that means to improve the design, structure, and implementation of the software, while preserving its functionality. At Oscar, we take this definition a step further. We improve our members’ experience by building trust through deep engagement, personalized guidance, and rapid iteration.
Last Trade: | US$20.66 |
Daily Change: | -0.78 -3.64 |
Daily Volume: | 10,007,193 |
Market Cap: | US$4.370B |
May 07, 2025 February 04, 2025 November 07, 2024 August 22, 2024 August 07, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load